A Randomized, Active-Controlled, Double-Blind, Phase 3 Study to Compare Pharmacokinetics, Efficacy, and Safety of CT-P17 With Humira in Patients With Moderate to Severe Chronic Plaque Psoriasis

This is a Phase 3 Study to Compare Pharmacokinetics, Efficacy and Safety of CT-P17 with Humira in Patients with Moderate to Severe Chronic Plaque Psoriasis

Start Date07 Nov 2022

Sponsor / Collaborator

Celltrion, Inc.

NCT04171414

/ CompletedPhase 3

A Phase III, Open-label, Single-arm, Multiple-dose Study to Evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Moderate to Severe Active Rheumatoid Arthritis

Clinical trial to evaluate Usability of Subcutaneous Auto-injector of CT-P17 in Patients With Active Rheumatoid Arthritis

Start Date09 Sep 2019

Sponsor / Collaborator

Celltrion, Inc.

[+1]

NCT04295356

/ CompletedPhase 1

A Phase 1, Randomized, Open-label, Two-arm, Parallel Group, Single-dose Study to Compare the Pharmacokinetics and Safety of the Auto-injector and Pre-filled Syringe of CT-P17 in Healthy Subjects

This study was phase 1, randomized, open-label, two-arm, parallel group, single-dose study, which was designed to compare the pharmacokinetics (PK) and safety of CT-P17 SC administration via AI and PFS in healthy subjects. Approximately 180 subjects were enraollend and randomly assigned to one of the two treatment arms in a 1:1 ratio. In each treatment arm, all subjects received a single dose (40 mg) of CT-P17 via either AI or PFS on Day 1 followed by 10 weeks during which PK, safety, and immunogenicity measurements were made. The randomization to treatment assignment was stratified by body weight (≥80 kg vs. <80 kg) as measured on baseline (Day -1), gender (male vs. female) and study center.

Start Date21 Jun 2019

Sponsor / Collaborator

Celltrion, Inc.

100 Clinical Results associated with Adalimumab biosimilar(Celltrion)

100 Translational Medicine associated with Adalimumab biosimilar(Celltrion)

100 Patents (Medical) associated with Adalimumab biosimilar(Celltrion)

Literatures (Medical) associated with Adalimumab biosimilar(Celltrion)

01 Jun 2026·Rheumatology and Therapy

Sex Differences in Treatment Expectations, Satisfaction and Tolerance After Switching to CT-P17, an Adalimumab Biosimilar: A Post Hoc Analysis of the YU-MATTER Study

Article

Author: Bouguen, Guillaume ; Foulley, Lucile ; Dellal, Azeddine ; Benkhalifa, Salim ; Marotte, Hubert ; Habauzit, Caroline ; Gossec, Laure

INTRODUCTION:

Data suggest that women and men differ in how they experience biological treatment. This post hoc analysis of the YU-MATTER study evaluated sex-related differences in patient satisfaction and perception when switching from adalimumab (reference or biosimilar) to CT-P17 (Yuflyma^®; Celltrion, Inc.), a high-concentration, citrate-free adalimumab biosimilar.

METHODS:

This analysis used data from the observational, multicentre, prospective YU-MATTER study. Patients had inflammatory bowel disease or chronic inflammatory rheumatic disease and switched from adalimumab (reference or low-concentration [< 50 mg/ml] biosimilar) to CT-P17. Patients completed online questionnaires monthly to month 3 (M3). The primary outcome was overall patient satisfaction (7-point Likert scale). Additional outcomes were expectations and perceptions of switching to CT-P17 (7- and 5-point Likert scale, respectively), beliefs about medicine (18-item Beliefs about Medicines Questionnaire), health literacy (16-item Health Literacy Survey Europe) and injection site reactions (pain and itching: 0-10 numerical rating scale; redness and haematoma: 4- and 3-point Likert scale, respectively).

RESULTS:

YU-MATTER enrolled 115 women and 117 men. More men than women reported satisfaction with CT-P17 treatment at M3 (82.1% vs 68.7%). Beliefs about medicines, health literacy, and patient expectations and perceptions of CT-P17 treatment did not differ significantly between sexes, although more women expected CT-P17 to be less painful (73.0% vs 59.0%; p = 0.077). At baseline, women reported significantly higher incidences of injection site redness (60.9% vs 48.7%) and haematoma (50.4% vs 26.5%) than men, with similar trends at M3 (40.0% vs 20.2% and 32.6% vs 8.5%, respectively), as well as significantly higher severity of injection site pain and itching. Both sexes reported fewer and less severe injection site reactions with CT-P17 at M3 compared with baseline adalimumab.

CONCLUSION:

Most expectations and perceptions of CT-P17 treatment were similar between sexes, but women experienced more injection site reactions. Further research is needed to understand why women experience a higher incidence of these reactions with adalimumab and its biosimilars.

TRIAL REGISTRATION:

Clinicaltrials.gov identifier NCT05427942 (registered June 22, 2022).

01 Dec 2025·SAGE Open Medical Case Reports

Perforating dermatosis in a young female patient receiving adalimumab biosimilar CTP-17 for chronic plaque psoriasis: A case report

Article

Author: Gisondi, Paolo ; Colato, Chiara ; Baravalle, Silvia ; Lozito, Alessia ; Bellinato, Francesco ; Poddine, Gabriele ; Fracassi, Elena ; Carletto, Antonio ; Girolomoni, Giampiero

Adalimumab, a tumor necrosis factor-alpha inhibitor, is widely used for chronic plaque psoriasis and psoriatic arthritis. While cutaneous adverse effects are known, perforating dermatosis is rare and poorly understood. A 34-year-old woman with psoriasis and psoriatic arthritis developed acquired perforating dermatosis after switching from adalimumab biosimilar GP2017–CTP17. She presented painful, ulcerated plaques on the thighs, gluteal area, and elbows. Histopathology confirmed the diagnosis. The biosimilar drug was discontinued and a 4-week course of systemic corticosteroids led to complete resolution. Both conditions were later managed with methotrexate and ixekizumab. Perforating dermatosis following anti-tumor necrosis factor is rare and underreported with adalimumab. No other known triggers (e.g., diabetes and renal failure) were present. Hypothesized mechanisms include fibronectin dysregulation and advanced glycation end accumulation, disrupting keratinocyte function. Perforating dermatosis should be recognized as a rare adverse effect of tumor necrosis factor-alpha inhibitors. Early recognition and discontinuation may prevent progression. Further studies are needed to clarify pathogenesis.

01 Sep 2025·ADVANCES IN THERAPY

Correction to: Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

Author: Choi, EunJin ; Brzewski, Paweł ; Baran, Wojciech ; Jaworski, Janusz ; Krogulec, Marek ; Jeon, DaBee ; Lee, HyunJin ; Cha, JungBin ; Dudek, Anna ; Kim, SungHyun ; Kolinek, Joanna ; Trefler, Jakub ; Choi, SuJin ; Owczarek, Witold ; Koo, John Y ; Sikora, Mariusz ; Lebwohl, Mark G ; Pariser, David M ; Daniluk, Stefan ; Bae, YunJu

News (Medical) associated with Adalimumab biosimilar(Celltrion)

27 Jul 2026

·www.celltrion.com

Celltrion Reports Q2 2026 Revenue of KRW 1.3937Tn and Operating Profit of KRW 451.8Bn; Record Quarterly Revenue as New Product Growth and Cost Improvements Boost Profitability

- Revenue up 45% and operating profit up 86.3% YoY, with a 32.4% operating margin demonstrating solid growth. - High-margin new products grew 76% YoY, accounting for 65% of total biologics revenue. - COGS ratio improved by 5.4 percentage points YoY, reflecting continued improvement in profitability. - Operating margin above 30% was achieved despite continued investment in R&D for future growth. - The company aims to exceed its annual guidance, supported by major market tenders and continued expansion of newly launched products in the second half. INCHEON, South Korea – Celltrion today announced that it recorded consolidated revenue of KRW 1.3937 trillion and operating profit of KRW 451.8 billion for the second quarter of 2026. The results represent year-over-year (YoY) increases of 45% in revenue and 86.3% in operating profit. Following a record quarterly revenue performance in the first quarter, the company also achieved its highest-ever quarterly revenue in the second quarter. Operating margin improved by 7.2 percentage points from a year earlier to 32.4%, demonstrating both strong top-line growth and enhanced profitability. Compared with the preliminary earnings announced on July 3, revenue increased by KRW 93.7 billion and operating profit rose by KRW 21.8 billion. The latest results reflect more than just revenue growth, highlighting qualitative growth driven by a portfolio shift toward new products and improved manufacturing efficiency. Stable sales of key products, strong global sales growth of newly launched high-margin products, and faster-than-expected cost structure improvements contributed to the performance. The results also demonstrated a virtuous business cycle in which profits from commercialized products provide stable financial support for research and development investments to fuel future growth. ▲ High-Margin New Products Continue Strong Growth Across Major Markets, Accounting for 65% of Biologics Revenue Second-quarter growth was driven by the rapid expansion of high-margin new products[1], while key products including Remsima, Truxima, and Herzuma maintained solid market positions. Truxima ranked No. 1 in market share in the United States, supported by expanded long-term supply agreements, while Remsima maintained its leading position across key markets. Herzuma achieved a record-high market share of 78% in Japan and exceeded 30% market share in Europe. Revenue from new products increased 76% YoY, expanding their contribution to total biologics revenue to 65%. By product, Remsima SC surpassed a 32% market share across the EU5[2] markets, while Zymfentra, the U.S. brand of Remsima SC, has continued to see steady uptake since launch. Yuflyma maintained its leading position in the European adalimumab market and continued to gain market share in the United States through expanded supply capabilities and distribution networks. Vegzelma maintained its leadership position in Europe and strengthened its U.S. growth foundation through formulary listings by two major pharmacy benefit managers (PBMs). Combined quarterly revenue from five newly launched products — Eydenzelt, Avtozma, Omlyclo, Stoboclo and Osenvelt, and Steqeyma — whose global rollout accelerated last year, exceeded KRW 300 billion, up 49% from the previous quarter. Celltrion plans to increase the share of biologics revenue generated by new products to approximately 70% in the second half of the year by continuing to expand launches into additional markets and broaden approved indications. ▲ COGS Ratio Improves to 38%; Product Mix and Manufacturing Efficiency Accelerate Profit Growth The cost of sales ratio improved to 38%, down 5.4 percentage points YoY and 2.1 percentage points from the previous quarter. The improvement was driven by a more favorable product mix resulting from the growing contribution of high-margin new products, as well as enhanced cost competitiveness through the depletion of high-cost inventory, higher production yields, and process optimization. This led to the emergence of operating leverage, with operating profit growth significantly exceeding revenue growth. The company expects profitability improvement to accelerate further in the second half as continued top-line growth generates greater economies of scale, alongside more efficient SG&A spending. The profitability improvement reflects a structural change driven by a shift in revenue mix toward new products and enhanced manufacturing competitiveness, rather than one-off factors. As the contribution of new products continues to increase, the foundation for stable earnings growth is expected to strengthen further. ▲ Operating Margin Exceeds 30% After Recognizing R&D Expenses for Future Growth Celltrion's second-quarter performance was particularly noteworthy compared with previous quarters, as the company achieved a 32.4% operating margin despite recognizing R&D expenses related to future growth. Celltrion continues to invest in R&D—from the discovery of follow-on biosimilars and novel drug candidates to preclinical and clinical studies, regulatory approval, and commercialization—and recognizes the related costs in current-period earnings. Unlike manufacturing-focused business models, this structure entails maintaining the profitability of current products while simultaneously bearing the investment burden required for future pipeline development. Yet Celltrion delivered an operating margin exceeding 30%, demonstrating that the cash-generating capability and the competitiveness of its business provide strong support for continued R&D investment. Celltrion continues to strengthen a business model in which commercial success supports investment in the development of follow-on biosimilars and novel drug candidates, driving new product launches and revenue growth. This has led to growing recognition that the company's value should be assessed not only on its current profitability, but also on the value of its pipeline and long-term growth prospects supported by sustained R&D investment. ▲ Expanding Biosimilar and Novel Drug Pipeline to Strengthen Future Growth Drivers Building on the launch of 11 biosimilars globally as of last year, Celltrion is accelerating development of its next-generation pipeline. The company plans to build a portfolio of 18 products by 2030, including biosimilars referencing autoimmune disease treatments such as Ocrevus, Cosentyx, and Taltz, as well as oncology therapies such as Keytruda and Darzalex. Supported by the ongoing trend toward relaxed clinical requirements among regulatory authorities, certain follow-on products are expected to benefit from reduced patient enrollment requirements, shorter development timelines, and lower R&D costs. In novel drug development, the company continues to expand its novel drug portfolio through both in-house R&D and open innovation initiatives, with programs spanning antibody-drug conjugates (ADCs), multispecific antibodies, and obesity treatments. Leveraging the stable cash flows generated by its biosimilar business, Celltrion aims to accelerate its transformation into a global biopharmaceutical company by delivering tangible R&D outcomes from its novel drug pipeline. ▲ Stronger Second-Half Growth Expected; Company Aims to Exceed Full-Year Guidance Celltrion expects second-half growth to exceed first-half performance as supplies under major tender contracts increase and newly launched products continue to gain market share across key markets. Driven by new product expansion into additional markets, U.S. PBM formulary coverage, deliveries under European public tenders, and year-end inventory stocking by distributors, the company aims to exceed its full-year targets of KRW 5.3 trillion in revenue and KRW 1.8 trillion in operating profit. A Celltrion official said, “Our second-quarter results demonstrated Celltrion’s cash-generating capability and business competitiveness, as we achieved an operating margin exceeding 30% while continuing to invest in R&D for future growth.” The official added, “We will continue to reinvest the stable cash flows generated by our biosimilar business into follow-on products and novel drug development, with the goal of exceeding our full-year performance targets and enhancing long-term corporate value.” [1] New products: Remsima SC (marketed as Zymfentra in the U.S.), Yuflyma, Vegzelma, Steqeyma, Stoboclo·Osenvelt, Avtozma, Omlyclo, and Eydenzelt [2] EU5: Germany, Spain, the United Kingdom, Italy, France

Financial StatementADCBiosimilar

07 Jul 2026

·www.celltrion.com

Celltrion’s Vegzelma completes formulary listings with two major U.S. PBMs, expanding reimbursement access to drive further U.S. growth

- Completed formulary listings with ESI’s public and private insurance plans and Optum’s public insurance plan, securing reimbursement coverage across 35% of the total U.S. insurance market - Vegzelma recorded 10.6% market share in the U.S. bevacizumab sector in May, with rapid growth expected through expanded reimbursement access - High-margin follow-up products including Omlyclo are scheduled to launch in the U.S. in H2, building on the performance of Celltrion’s existing portfolio [July 7, 2026, KST] Celltrion today announced that Vegzelma (bevacizumab), its treatment for metastatic colorectal cancer and breast cancer, has successfully secured formulary listings with two major pharmacy benefit managers (PBMs) in the United States, establishing a foundation for reimbursement coverage. As Vegzelma has already achieved a market share of over 10% through ‘open market’-focused sales activities, this latest achievement is expected to further accelerate its market share expansion. Vegzelma has recently been listed as a preferred drug on the government and commercial insurance formularies of Express Scripts (ESI), one of the top three PBMs in the United States, as well as on the government insurance formulary of Optum, another major PBM. Reimbursement coverage for ESI government plans and Optum has already taken effect from July 1, while reimbursement coverage for ESI commercial plans is scheduled to begin in January next year. In the U.S. pharmaceutical market, the top three PBMs hold significant influence, accounting for approximately 80% of the total insurance market. If a drug is not listed on formularies managed by PBMs, patients are required to purchase the product at its full price without reimbursement, making access to high-cost treatments practically difficult. Through these PBM formulary listings, Vegzelma has secured reimbursement coverage across more than 35% of the U.S. insurance market, establishing a stable foundation for prescription growth. According to IQVIA, Vegzelma recorded approximately 10.6% market share in the U.S. bevacizumab sector as of May, surpassing double-digit market share for the first time since launch and continuing its growth momentum. This result was achieved through Celltrion USA’s focused strategy targeting the U.S. bevacizumab open market and is considered particularly meaningful as Vegzelma delivered strong performance despite entering the market as a latecomer in a highly competitive environment. The open market is a channel supported by the U.S. government that directly connects healthcare institutions and pharmaceutical companies, where a company’s sales capabilities and product competitiveness serve as key factors for market penetration. With these formulary listings, Vegzelma is expected to further accelerate its market share growth by adding new reimbursement access from insurers to the existing growth momentum generated in the open market. Celltrion plans to continue pursuing formulary listing negotiations with other major PBMs to further strengthen Vegzelma’s growth trajectory. In addition to Vegzelma, Celltrion’s other key products, including SteQeyma (ustekinumab) and Yuflyma (adalimumab), are also continuing to perform well in the U.S. market. The two products recorded market shares of 13.3% and 8.1%, respectively, in the U.S. in May, demonstrating stable prescription growth. Also, SteQeyma ranked second in prescription volume among ustekinumab biosimilars despite intense competition following the launch of seven biosimilar products, underscoring the direct sales competitiveness of Celltrion USA. Alongside the performance of its existing products, Celltrion’s U.S. revenue growth is expected to continue as high-margin follow-up products are launched. In the second half of the year, the subcutaneous (SC) formulation of Avtozma (tocilizumab), a treatment for autoimmune diseases, and Omlyclo (omalizumab) are scheduled to be newly launched in the U.S., further strengthening the company’s portfolio. Also, Omlyclo is expected to launch in the U.S. as a first-mover omalizumab biosimilar, positioning it to rapidly capture the market based on its competitive advantage. “Vegzelma has secured a reimbursement foundation in the U.S. by being listed as a preferred drug on the formularies of major PBMs with significant market influence, and we expect this to further accelerate prescription growth,” said an official from Celltrion. “We will continue to pursue formulary listing negotiations with other major PBMs to build on Vegzelma’s achievements, while strengthening the sales performance of Celltrion’s broader portfolio and expanding our market influence in the United States.”

Biosimilar

21 Apr 2026

·www.prnewswire.com

Celltrion to present seven abstracts in inflammatory bowel disease (IBD) at 2026 Digestive Disease Week® (DDW)

Seven abstracts accepted for presentation include data from long-term follow-up studies and a post-hoc analysis of the pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA® (infliximab-dyyb) Findings emphasize clinical decision-making in long-term management of inflammatory bowel disease (IBD), reinforcing Celltrion's commitment to elevating the standard of care and addressing unmet medical need in gastroenterology April 21, 2026 -- Celltrion, Inc. today announced that seven abstracts will be presented at the 2026 Digestive Disease Week® (DDW) Annual Meeting, taking place May 2-5 in Chicago, Illinois. The oral and poster presentations will feature data including post-hoc analysis of its pivotal LIBERTY studies (LIBERTY-CD and LIBERTY-UC) of ZYMFENTRA®, the first and only FDA-approved subcutaneous infliximab. "The findings provide additional evidence that disease control can be effectively recaptured with a convenient subcutaneous option, with the potential to advance the treatment paradigm for people living with Crohn's disease and ulcerative colitis," said Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. "The research Celltrion is presenting at DDW reflects our ongoing commitment to transforming IBD care through innovative therapies that improve patient outcomes." Celltrion is driving scientific discovery and expanding access to comprehensive clinical and real-world evidence to support informed treatment decisions in an increasingly complex and evolving IBD landscape. ZYMFENTRA® (infliximab-dyyb) is a prescription medicine used as an injection under the skin (subcutaneous injection) by adults for the maintenance treatment of moderately-to-severely active ulcerative colitis following treatment with an infliximab product given by intravenous infusion (IV), Moderately-to-severely active Crohn's disease following treatment with an infliximab product given by intravenous infusion (IV). ZYMFENTRA blocks the action of tumor necrosis factor-alpha (TNF-alpha), a protein that can be overproduced in response to certain diseases and cause the immune system to attack normal, healthy parts of the body. ZYMFENTRA was approved by the FDA through the Biologics License Application (BLA) under the 351 (a) pathway of the Public Health Service Act (a "stand-alone" BLA). ZYMFENTRA is considered a new biologic with a first-approved subcutaneous administration form and thus will be under patent protection for its dosage form by 2037 and for its route of administration by 2040. Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA), the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW is an in-person and online meeting from May 2-5, 2026. Celltrion is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people's lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world's first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. Celltrion USA is Celltrion's U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion's FDA-approved biosimilar products in immunology, oncology, hematology, and endocrinology include: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (ustekinumab-stba), STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), OMLYCLO® (omalizumab-igec), and EYDENZELT® (aflibercept-boav) as well as the novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion's unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. The content above comes from the network. if any infringement, please contact us to modify.

Drug ApprovalClinical Result

100 Deals associated with Adalimumab biosimilar(Celltrion)

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	L04AB04	DB00051

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Polyarticular Juvenile Idiopathic Arthritis	Australia	Celltrion Healthcare Australia Pty Ltd.	25 Mar 2022
Ankylosing Spondylitis	European Union	Celltrion Healthcare Hungary Kft	11 Feb 2021
Ankylosing Spondylitis	Iceland	Celltrion Healthcare Hungary Kft	11 Feb 2021
Ankylosing Spondylitis	Liechtenstein	Celltrion Healthcare Hungary Kft	11 Feb 2021
Ankylosing Spondylitis	Norway	Celltrion Healthcare Hungary Kft	11 Feb 2021
Arthritis, Psoriatic	European Union	Celltrion Healthcare Hungary Kft	11 Feb 2021
Arthritis, Psoriatic	Iceland	Celltrion Healthcare Hungary Kft	11 Feb 2021
Arthritis, Psoriatic	Liechtenstein	Celltrion Healthcare Hungary Kft	11 Feb 2021
Arthritis, Psoriatic	Norway	Celltrion Healthcare Hungary Kft	11 Feb 2021
Axial Spondyloarthritis	European Union	Celltrion Healthcare Hungary Kft	11 Feb 2021
Axial Spondyloarthritis	Iceland	Celltrion Healthcare Hungary Kft	11 Feb 2021
Axial Spondyloarthritis	Liechtenstein	Celltrion Healthcare Hungary Kft	11 Feb 2021
Axial Spondyloarthritis	Norway	Celltrion Healthcare Hungary Kft	11 Feb 2021
Colitis, Ulcerative	European Union	Celltrion Healthcare Hungary Kft	11 Feb 2021
Colitis, Ulcerative	Iceland	Celltrion Healthcare Hungary Kft	11 Feb 2021
Colitis, Ulcerative	Liechtenstein	Celltrion Healthcare Hungary Kft	11 Feb 2021
Colitis, Ulcerative	Norway	Celltrion Healthcare Hungary Kft	11 Feb 2021
Crohn Disease	European Union	Celltrion Healthcare Hungary Kft	11 Feb 2021
Crohn Disease	Iceland	Celltrion Healthcare Hungary Kft	11 Feb 2021
Crohn Disease	Liechtenstein	Celltrion Healthcare Hungary Kft	11 Feb 2021

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic large plaque psoriasis	Phase 3	Estonia	Celltrion, Inc.	07 Nov 2022

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


ECCO2026	Not Applicable	Perianal fistula due to Crohn's disease \| Colitis, Ulcerative	191	Adalimumab Dose Intensification	stifgveqim(izxoqmlthj) = gfqwbsonds rfxagxuuna (rfklilnbpm ) View more	Positive	18 Feb 2026
				No Dose Intensification	stifgveqim(izxoqmlthj) = qoloxpmrlv rfxagxuuna (rfklilnbpm ) View more
NCT05495568 (CT-P17, Pubmed \| Dermatol Ther (Heidelb))	Phase 3	Plaque psoriasis	327	CT-P17	elthegjczr(ijfaewkxzm) = nqvojfwvoz wuigflobyl (bfgpknyfph, 16.59)	Positive	27 Mar 2025
NCT03789292 (Pubmed \| Arthritis Res Ther)	Phase 3	Rheumatoid Arthritis	648	CT-P17	fhjhjuekgh(zowurtlfxg) = lvonjtxryb zttwsphqll (sthpffpmvv )	Positive	01 Dec 2021
				EU-adalimumab	fhjhjuekgh(zowurtlfxg) = ocvxjowkoi zttwsphqll (sthpffpmvv )
NCT04171414 (CTgov)	Phase 3	Rheumatoid Arthritis	62	CT-P17 SC AI (adalimumab)	hybwoljyou(ektmjousrf) = jbpxjabcez hxjteftlpx (dyexapetxm, 2.131) View more	-	17 Nov 2021
EULAR2021	Not Applicable	Rheumatoid Arthritis Maintenance	648	CT-P17	sarenukpvp(sfahqkczoe) = hzphqnhniy sqnvayrosf (ndnajuyudv ) View more	-	02 Jun 2021
NCT03970824 (CTgov)	Phase 1	-	312	CT-P17 (CT-P17)	mhkavaeiui(epbnebnnek) = ivbiqpwxni plcvrnyfld (foxvkdogxz, 1150.16) View more	-	11 Dec 2020
				Humira (US-licensed Humira)	mhkavaeiui(epbnebnnek) = ewzktrfpiz plcvrnyfld (foxvkdogxz, 917.47) View more
NCT04295356 (CTgov)	Phase 1	-	180	CT-P17 (Auto Injector)	gnpvkhdoiy(ivajeqnpeb) = wnsfyqjiad uxaefmkmgt (yhjvexegjn, 1.5479) View more	-	07 Dec 2020
				CT-P17 (Pre-filled Syringe)	gnpvkhdoiy(ivajeqnpeb) = vxlugvgknd uxaefmkmgt (yhjvexegjn, 1.2620) View more
ACR2019	Not Applicable	-	-	CT-P17 40 mg	morjeyrqug(gearclowbr) = vdquwidvct sbxvguuhgo (ogbxmhtsql ) View more	-	10 Nov 2019
				EU-reference adalimumab 40 mg	morjeyrqug(gearclowbr) = yqoigejrhp sbxvguuhgo (ogbxmhtsql ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis